Critical Comparison: Adamas Pharmaceuticals (ADMS) & Its Peers

Adamas Pharmaceuticals (NASDAQ: ADMS) is one of 185 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Adamas Pharmaceuticals to related businesses based on the strength of its risk, valuation, institutional ownership, analyst recommendations, dividends, profitability and earnings.


This table compares Adamas Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adamas Pharmaceuticals N/A -68.00% -53.83%
Adamas Pharmaceuticals Competitors -3,506.45% -98.63% -40.60%

Earnings & Valuation

This table compares Adamas Pharmaceuticals and its peers gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Adamas Pharmaceuticals $570,000.00 -$60.05 million -7.95
Adamas Pharmaceuticals Competitors $213.24 million -$39.02 million -54.23

Adamas Pharmaceuticals’ peers have higher revenue and earnings than Adamas Pharmaceuticals. Adamas Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

70.6% of Adamas Pharmaceuticals shares are held by institutional investors. Comparatively, 46.3% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 29.0% of Adamas Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Adamas Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Adamas Pharmaceuticals’ peers have a beta of 1.47, meaning that their average share price is 47% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Adamas Pharmaceuticals and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adamas Pharmaceuticals 0 0 7 0 3.00
Adamas Pharmaceuticals Competitors 501 2331 6432 121 2.66

Adamas Pharmaceuticals currently has a consensus target price of $42.00, suggesting a potential upside of 57.24%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.35%. Given Adamas Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Adamas Pharmaceuticals is more favorable than its peers.


Adamas Pharmaceuticals beats its peers on 7 of the 12 factors compared.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Leave a Reply